Stockscreener 앱 받기
13.08
0.38%
0.05
전일 마감가:
$13.03
열려 있는:
$13.11
하루 거래량:
47,228
Relative Volume:
0.40
시가총액:
$644.16M
수익:
-
순이익/손실:
-
주가수익비율:
-19.45
EPS:
-0.6724
순현금흐름:
-
1주 성능:
+3.40%
1개월 성능:
+26.62%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$12.54
$13.27
1주일 범위
$12.32
$13.95
52주 변동 폭
$8.75
$17.82
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Compare AGMB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGMB
Agomab Therapeutics Nv Adr
|
13.08 | 644.16M | 0 | 0 | 0 | -0.6724 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-03 | 개시 | JP Morgan | Overweight |
| 2026-03-03 | 개시 | Leerink Partners | Outperform |
| 2026-03-03 | 개시 | Morgan Stanley | Overweight |
Agomab Therapeutics Nv Adr 주식(AGMB)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView
AGMB Forecast — Price Target — Prediction for 2027 - TradingView
Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com
Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com
Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.
Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate
Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail
AgomAb (NASDAQ: AGMB) posts €62.5m loss and funds operations into 2029 - Stock Titan
AGMB Technical Analysis | Trend, Signals & Chart Patterns | AGOMAB THERAPEUTICS NV (NASDAQ:AGMB) - ChartMill
United Health Group, Viacom among market cap stock movers on Tuesday - Investing.com
Reviewing Prime Medicine (NASDAQ:PRME) and AgomAb Therapeutics (NASDAQ:AGMB) - Defense World
Agomab receives U.S. patent for lung fibrosis drug candidate By Investing.com - Investing.com India
Agomab receives U.S. patent for lung fibrosis drug candidate - Investing.com
Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView
EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView
Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Net income of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView
EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView
Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView
Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Agomab Therapeutics Nv Adr (AGMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):